Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.

作者:Ranxia, Gong; Haichuan, Hu; Haiquan, Chen
来源:Journal of Clinical Oncology, 2016, 34(15_suppl): e20026-e20026.
DOI:10.1200/jco.2016.34.15_suppl.e20026

全文